Details for New Drug Application (NDA): 205004
✉ Email this page to a colleague
The generic ingredient in BORTEZOMIB is bortezomib. There are twenty drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the bortezomib profile page.
Summary for 205004
Tradename: | BORTEZOMIB |
Applicant: | Fresenius Kabi Usa |
Ingredient: | bortezomib |
Patents: | 1 |
Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 205004
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | POWDER;INTRAVENOUS | Strength | 3.5MG/VIAL | ||||
Approval Date: | Nov 6, 2017 | TE: | RLD: | No | |||||
Patent: | ⤷ Try a Trial | Patent Expiration: | Nov 3, 2032 | Product Flag? | Y | Substance Flag? | Delist Request? |
Complete Access Available with Subscription